Company intelligence / Profile preview
VBI Vaccines Inc.
- Ownership
- Public · VBIV
- Employees
- ~30
- Development stage
- Commercial
Overview
VBI Vaccines had one FDA-approved product, PreHevbrio, a three-antigen hepatitis B vaccine that generated $3.1 million in sales in 2023. The company filed for bankruptcy in July 2024 and initiated a voluntary recall of PreHevbrio in October 2024 due to termination of operations[8][9].
- Therapeutic areas
- OncologyInfectious Diseases
- Modalities
- VaccinesImmunotherapeuticsVirus-like particles (VLPs)Enveloped virus-like particles (eVLPs)mRNA-launched eVLPs (MLE)
- Industry
- Biotech
Drug pipeline
13 assets12 more assets in the full pipeline.
Request access →Partnerships
Financials
- Market cap
- $1.9M
- Total revenue
- $1.2M
- Enterprise value
- $42M
Beyond the preview
Go deeper on VBI Vaccines Inc..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on VBI Vaccines Inc..